Galytx, a University of Liverpool spin-out, is developing small molecule inhibitors of galectin-3, which may have therapeutic potential across multiple indications. To support the commercial viability of these assets, Galytx engaged Nexcea to translate the anticipated mode-of-action benefits into clinical and patient outcomes, validated by expert clinicians, and ultimately into quantified economic messages intended to resonate with investors and reimbursement bodies.

Nexcea aimed to estimate potential NHS resource and budget savings associated with galectin-3 inhibition in certain types of cancer, providing an early economic rationale to investors regarding the commercial potential of the assets. The project sought to develop clear, intuitive value statements linking clinical benefits to economic impact and establish a provisional price point for the NHS.

Our activities included:

• Conducting desk research to identify and estimate published treatment costs for certain types of cancer in the UK.

• Identifying and interviewing experienced cancer specialists to validate findings.

• Preparing a briefing document outlining the intervention, key discussion topics, and pre-read materials for the clinician ahead of the interview.

• Conducting a semi-structured interview via Teams, recorded for analysis, with the Galytx team invited to participate.

• Developing a report outlining health economic arguments and value statements.

Nexcea provided Galytx with an evidence-based economic narrative, translating early-phase mode-of-action data into potential NHS cost savings. The analysis was intended to strengthen investor confidence by offering an indication of pricing viability, allowing potential investors to assess the commercial prospects of galectin-3 inhibition. By integrating real-world clinical perspectives, the research helped validate the potential role of the intervention within the cancer treatment landscape. Furthermore, the findings laid the groundwork for future cost-effectiveness modelling and reimbursement planning as the asset progresses through development.

“Nexcea’s structured and pragmatic approach enabled us to translate our scientific advancements into an economic rationale. The insights provided have been valuable in shaping our commercial strategy.”

Karen Sullivan, CEO, Galytx